COVID-19 Laboratory Billing Information

Quadax is dedicated to keeping our laboratory clients up-to-date on the billing, reporting, and procedural information specific to each payer as it pertains to COVID-19.

Click here for additional COVID-19 Payer Information 

Latest Updates

Indicates most recent updates 

Date Payers and Organizations Overview
2/1/2022 Aetna

UPDATE - COVID-19 News February 2022. COVID-19 Testing - We cover COVID-19 testing without cost sharing when medically necessary. We do not cover testing for returning to work or school, or for surveillance purposes or travel purposes. The patient is responsible for the full cost of testing if the billed place of service is work or school. READ MORE

UPDATE - Aetna is complying with the CMS coding guidelines for COVID-19 lab testing. 
READ MORE 


>>>Click here to read past updates

2/23/2022 American Medical Association (AMA)

AMA Updates/Category I and Proprietary Laboratory Analyses (PLA). Review and download the full CPT code descriptor release. READ MORE 
The descriptors documents on this page do not include the COVID-19 vaccine CPT codes. Further updates to these documents will only occur when there are additional modifications to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) codes other than vaccines.

2/21/2022 - AMA/CPT Category I and PLA Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (CARS-CoV-2) (coronavirus disease {COVID-19}). Most recent changes to this long descriptor document. READ MORE 

4/29/2020 Amerigroup Member cost shares will be waived for COVID-19 lab tests performed by participating and non-participating providers. Lab testing should be billed with codes U0001, U0002, U0003, U0004, 86328, 86769 or 87635. READ MORE
5/8/2020 Anthem California

UPDATE - Prior authorizations are not required from Anthem or it's delegated entities for screening or testing related to Covid-19. READ MORE

>>>Click here to read past updates

4/22/2020 Anthem Colorado, Indiana, Kentucky, Missouri, Ohio, Wisconsin Payer is encouraging providers to bill with codes U0001, U0002, U0003, U0004, 86328, 86769, or 87635 based on the test provided. READ MORE
1/18/2022  Blue Cross Blue Shield 
Texas

UPDATE -Labs for Prompt COVID-19 Testing. READ MORE 

Over-the-Counter (OTC) Tests: We cover COVID-19 diagnostic tests members buy without a provider’s involvement or prescription, starting Jan. 15, 2022, through the end of the federal public health emergency. OTC tests must be FDA-authorized. This applies to fully insured, self-insured and individual and family plans. Members can buy up to eight tests per covered member every 30 days. This program is through BCBSTX and Prime TherapeuticsTM pharmacy benefits. If a member does not have benefits through Prime Therapeutics, they should contact their pharmacy benefit administrator. More information is on our member microsite.


>>>Click here to read past updates

10/5/2021 CAP College of American Pathologists

UPDATE - CAP Advocacy Update 10/5/21. CAP Urges Senate Leaders to Include Insurance Access Provisions in Reconciliation Bill. READ MORE

With Senate lawmakers continuing to debate a budget reconciliation package, the CAP engaged with Senate leadership to expand access to health care insurance coverage, improve the pandemic response with a national testing strategy, and address health inequities. In a September 30 letter to Senate leaders, the CAP asked lawmakers to stop upcoming cuts to pathologists’ Medicare payments and address physician shortages throughout the United States.

 

>>>Click here to read past updates

5/16/2022 Centers for Disease Control
and Prevention (CDC)

UPDATE - Lab Advisory 5/16/22: HHS to Discontinue Providing Viral Transport Media to States and Jurisdictions. READ MORE
Effective May 23, 2022, the U.S. Department of Health and Human Services (HHS) will no longer distribute viral transport media (VTM) to states and jurisdictions. Laboratories and testing facilities that receive supplies from their state health departments should note these changes and plan accordingly.

5/12/2022 - Lab Update 5/12/22: Join the Next Clinical Laboratory COVID-19 Response Call on Monday, June 27th. READ MORE 
DC’s Division of Laboratory Systems will host a call to discus
s hot topics and to solicit the laboratory community’s questions about the national response to the COVID-19 pandemic. The Clinical Laboratory COVID-19 Response Calls take place on the third Monday of each month and are scheduled for one hour. 

5/11/2022 - Lab Alert 5/11/22: Do Not Use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold). READ MORE 
On May 10, 2022, the U.S. Food and Drug Administration (FDA) issued a safety communication to warn people not to use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold). FDA has not authorized, cleared, or approved this test for distribution or use in the United States. FDA is concerned about the risk of false results when using this test because the manufacturer has not provided FDA with adequate data to show that these tests work correctly.

5/3/2022 - Lab Alert 5/3/22: Counterfeit COVID-19 Self-Tests. The U.S. Food and Drug Administration (FDA) has recently published a website about counterfeit COVID-19 self-tests. READ MORE

5/2/2022 - Lab Alert 5/2/22: Celltrion USA Recalls Certain Point-of-Care DiaTrust COVID-19 Ag Rapid Test Kits. READ MORE 

4/20/2022 - Lab Update 4/20/2022. The Clinical Laboratory COVID-19 Response Calls take place on the third Monday of each month and are scheduled for one hour. The next call is scheduled for Monday, May 16. READ MORE 
CDC’s Division of Laboratory Systems will host a call to discuss hot topics and to solicit the laboratory community’s questions about the national response to the COVID-19 pandemic. For more information, visit the Clinical Laboratory COVID-19 Response Call website.

3/31/2022 - Lab Update 3/31/22. The U.S. Centers for Disease Control and Prevention (CDC) will host a virtual meeting of the Clinical Laboratory Improvement Advisory Committee (CLIAC) on April 13 and 14, 2022 from 11:00 AM to 6:00 PM EDT each day. READ MORE
Presentations and CLIAC discussion will focus on the future of laboratory medicine, especially testing in non-traditional sites. There will be an extended public comment session that focuses on anticipated changes in testing practices, personnel issues, and emerging technologies used in non-traditional testing sites. Agenda and meeting documents will be shared on the CDC CLIAC website when available. No registration is required for this Zoom virtual meeting.

3/24/2022 - Lab Alert 3/24/22. On February 8, 2022, BioRad issued a voluntary recall for the RPR portion of the BioPlex 2200 Syphilis Total & RPR Test Kit. The U.S. Food and Drug Administration (FDA) classified this as a Class 2 Device Recall on March 16, 2022. READ MORE 

3/22/2022 - Lab Advisory 3/22/22: Upcoming Schedule Changes for Clinical Laboratory COVID-19 Response Calls. READ MORE 
The CDC Division of Laboratory Systems (DLS) is announcing the following schedule changes for the Clinical Laboratory COVID-19 Response Calls:

  • The Clinical Laboratory COVID-19 Response Call on Monday, April 4 is cancelled.
  • Beginning Monday, April 18, the Clinical Laboratory COVID-19 Response Calls will move to a monthly schedule.
  • Future Clinical Laboratory COVID-19 Response Calls will take place on the third Monday of each month and will be scheduled for one hour.

3/21/2022 - Lab Alert 3/21/22: FDA Recalls Specific Lot Numbers of Celltrion DiaTrust™ COVID-19 Ag Rapid Test. READ MORE 

3/2/2022 - Lab Advisory 3/10/22. HHS Updates COVID-19 Laboratory Reporting Guidance. On March 8, 2022, the U.S. Department of Health and Human Services (HHS) updated its Laboratory Data Reporting Guidance. READ MORE 

3/2/2022 - Lab Alert 3/2/22. FDA Says Do Not Use These Unauthorized COVID-19 Tests. READ MORE 
On March 1, 2022, the U.S. Food and Drug Administration (FDA) issued three safety communications:

** Do Not Use Certain Celltrion DiaTrust COVID-19 Tests
** Do Not Use SD Biosensor STANDARD Q COVID-19 Ag Home Tests
** Do Not Use Certain ACON Flowflex COVID-19 Tests

FDA is concerned about the risk of false results when using these unauthorized tests. We encourage you to review these safety communications in detail and share this message widely with your networks.

 

>>>Click here to read past updates

1/13/2022 Centers for Medicare & Medicaid Services (CMS)

UPDATE - Clinical Lab Fee Schedule - Revised. Note the upcoming changes to the payment rules for independent labs when collecting specimens from homebound patients and inpatients.
READ MORE 

MLN Fact Sheet Clinical Laboratory Fee Schedule MLN006818 December 2021 - Page 3 of 5:
The CLFS pays a nominal fee for specimen collection for laboratory testing and a fee to cover transportation and personnel expenses (generally referred to as the travel allowance) for trained personnel to collect specimens from homebound patients and inpatients (except hospital inpatients). Medicare pays the travel allowance only when the nominal specimen collection fee is also payable.
To make diagnostic testing available to Medicare patients during the COVID-19 public health emergency (PHE), we changed Medicare payment rules to pay independent labs for specimen collection from homebound patients and inpatients (not in a hospital) for COVID-19 CDLTs under certain circumstances and increased payments from $3-$5 to $23-$25. The increased fees will end at the termination of the COVID-19 PHE.

                          

>>>Click here to read past updates

4/6/2021 Cigna

UPDATE - Cigna covers diagnostic molecular and antigen tests for COVID-19 through April 20, 2021 without cost-share when an individual seeks and receives a diagnostic test from a licensed or authorized health care provider, or when a licensed or authorized health care provider refers an individual for a COVID-19 diagnostic test. READ MORE 

>>>Click here to read past updates
11/5/2020 Excellus Blue Cross Blue Shield

UPDATE - Modifier CG Clarification for COVID-19 Viral and Antibody Testing (Audience: Participating Physicians, Hospitals, Facilities and Laboratories). READ MORE 


>>>Click here to read past updates

4/5/2022 First Coast Service Options -
JN A & B

UPDATE - Fee Schedule News 4/5/22. COVID-19: Allowances for Laboratory Test Codes.
READ MORE 

Allowances are now available for new codes for COVID-19 testing. Codes 0202U, 0223U, 0224U, and 87426 were added effective June 25. Codes 0225U, 0226U, 86408, and 86409 were added effective August 10. Code 86413 was added effective September 8. Codes 0240U, 0241U, 87635, 87636, 87637, and 87811 were added effective October 6. Code 87428 was added effective November 10. Codes U0003 and U0004 were removed; they were added to the clinical laboratory fee schedule January 1. Code 87913 was added effective February 21.

2/27/2022 - 2022 Payment Rates for COVID-19 vaccine and monoclonal administration.
READ MORE

CMS established national payment allowances for the administration of COVID-19 vaccines and monoclonal antibodies. These allowances will be geographically adjusted for many providers. The First Coast allowances for jurisdiction N (JN) for administration of COVID-19 vaccines and monoclonal antibodies for 2022 are below.

First Coast Claims Processing Issue for Part B Providers; Posted 1/25/2022. Revised editing for ordering/referring providers on lab claims. READ MORE

Issue - Because of the COVID-19 public health emergency (PHE), CMS previously amended regulations to remove the requirement that certain diagnostic tests are covered only when ordered by the treating physician. With this revised policy, Medicare beneficiaries may receive coverage for one COVID-19 and related test without the order of a physician or non-physician practitioner. This revised policy includes the following codes: U0001-U0004, 87635, 86769, 86328, 87275, 87276, 87279, 87400, 87501-87503, 87631, 87804, 87280, 87420, 87634, and 87807.
Resolution - CMS has revised this editing to remove the ordering requirement from additional codes. This revised editing will be applicable to the following codes for dates of service on or after March 1, 2020: U0005, 86408, 86409, 86413, 87426, 87811, 0224U, 0226U, 87428, 87636, 87637, 0240U, 0241U, G2023, and G2024. The relaxation of the referring provider for the listed codes is effective for dates of service on or after March 1, 2020.
The referring/ordering provider NPI will be required for procedure codes 87632 and 87633 effective for claims processed on or after May 4, 2021.
Status/date resolved - Open
Provider action - If you think your claim denied in error due to missing ordering provider, includes one of the codes listed above, and is for a date of service on or after March 1, 2020, you can request a history correction reopening using the Claim Reopening Gateway. For instructions on performing adjusts using the Claim Reopening Gateway, please view the Help Guide.

UPDATE - Provider Specialty News/Clinical Lab/Part B. Duplicate editing for COVID-19 laboratory services. READ MORE 

Generally, duplicate editing prevents allowing payment on claims lines that contain the same procedure code as previously paid lines. First Coast understands that if initial testing is negative but the suspicion for COVID-19 remains and determining the presence of infection is important for management or infection control, repeating the test should be allowed.

First Coast has duplicate editing in the Part B claims processing system (Multi-Carrier System [MCS]) for the COVID-19 laboratory codes U0001, U0002, U0003, U0004, and 87635. The system editing will allow payment for repeated tests on the same date of service. The claim lines for the repeated laboratory service should be billed with the applicable modifier, 59 or 91.


>>>Click here to read past updates

1/25/2022 Food and Drug Administration (FDA)

UPDATE - FDA Roundup News 1/25/22. READ MORE 
** On Jan. 21, the FDA updated the In Vitro Diagnostics EUAs – Molecular and Antigen Diagnostic Tests for SARS-CoV-2 web pages to share the latest information. The update added details about the design of SARS-CoV-2 diagnostic tests, including:

^ Which authorized molecular and antigen diagnostic tests are designed with single or multiple viral targets.
^ Tests with single targets are more susceptible to changes in performance due to viral mutations, meaning they are more likely to fail to detect new variants. Tests with multiple targets are more likely to continue to perform well when new variants emerge.

COVID-19 Update 12/7/21. The FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information, including FDA recommendations for clinical laboratory staff and health care providers. READ MORE 

The update also added new information about SARS-CoV-2 tests whose performance could be impacted by SARS-CoV-2 genetic mutations, specifically those found in the omicron variant, in patient samples. This includes a list of tests where viral mutations cause a specific detection pattern that may help to signal the presence of the omicron variant, but genetic sequencing would be needed to confirm. Since the tests on this list are designed to detect multiple genetic targets, it is expected these tests will continue to detect SARS-CoV-2 including when the omicron variant is present.

The FDA also added the Tide Laboratories, LLC, DTPM COVID-19 RT-PCR Test to another list of impacted tests. Since the Tide Laboratories test is a single target test that targets a portion of the N-gene where deletions occur with the omicron variant, the test is expected to fail to detect the SARS-CoV-2 omicron variant. In the update, we include laboratories where the test is performed. To note, it is not believed to be used for high volume testing.

 

>>>Click here to read past updates

11/15/2021  Department of Health and Human Services (HHS)

UPDATE - Laboratory-Developed Tests. The U.S. Department of Health and Human Services and the Food and Drug Administration are committed to helping ensure that COVID-19 tests are accurate, reliable, and available. As part of that commitment, HHS is withdrawing a policy established during the previous administration that limited FDA’s ability to address certain problematic COVID-19 tests. READ MORE 

The policy, first announced on August 19, 2020, related specifically to “laboratory developed tests” (LDTs). An LDT is a type of test that is generally designed, manufactured, and used in a single laboratory. The policy directed FDA not to require premarket review for LDTs, including premarket approval (PMA) or clearance (510(k)), and emergency use authorization (EUA), even in situations where they have poor performance.

By withdrawing the policy, HHS is helping to ensure that COVID-19 tests work as intended. Effective today, HHS no longer has a policy on LDTs that is separate from FDA’s longstanding approach in this area.

FDA also updated its policies for COVID-19 tests, including COVID-19 LDTs. These policies take into account the importance of test availability, reliability, and accuracy.

>>>Click here to read past updates

6/11/2020 Highmark

UPDATE - COVID-19 Molecular Testing. The following codes have been created for providers and laboratories to allow billing for COVID-19 patient diagnostic tests. READ MORE

>>>Click here to read past updates

2/17/2021 Horizon BCBC New Jersey

Effective January 1, 2021 and throughout the period of public health emergency, Horizon BCBSNJ shall consider an additional add-on payment (U0005) for COVID-19 diagnostic testing run on high throughput technology, when billed with procedure code U0003 or U0004, and when the following conditions are met:

• U0003 or U0004 COVID-19 testing is completed in two (2) calendar days or less for the specific test billed, and
• The laboratory can certify that 51% of the previous months U0003 and U0004 COVID-19 diagnostic testing was completed within two (2) calendar days or less.

>>READ MORE

2/17/2021 HRSA Beginning, January 1, 2021, Medicare will reimburse independent laboratories $75 per claim (HCPCS codes U0003 and U0004) with a potential add-on reimbursement of $25 (HCPCS code U0005) if the laboratory returned results to patients within 48 hours and returned results for a majority of its tests (Medicare and non-Medicare) during the previous calendar month within two days. READ MORE

3/26/2020 Humana

Lab providers should use the newly created HCPCS codes when billing for COVID-19 testing.  Member cost-share waivers for COVID-19-related testing have been expanded, which includes both the COVID-19 test and viral panels that rule out COVID-19; cost-share waivers now apply to laboratory testing, specimen collection and certain related services that result in the ordering or administration of the test, including, physician office or emergency department visits. This change will apply on a retroactive basis to services delivered on or after March 6, 2020.  READ MORE

3/16/2020 Independence Blue Cover and reimburse member cost-sharing (such as co-pays, deductibles, and coinsurance) for the COVID-19 test and the administration of the test when performed at a physician’s office, urgent care center, or an emergency room. Treatment for COVID-19 is subject to the specific out-of-pocket cost-sharing for each member’s health plan.  This includes members enrolled in fully insured plans, employer-sponsored plans, Medicare Advantage and the individual and family plans available through the Affordable Care Act. Self-funded plans will be able to opt-out of this program. In addition, IRS guidance, released March 11, allows for testing and treatment services before the deductible is met for members with high-deductible health plans and health savings accounts (HSAs).  Independence continues to cover medically necessary health care costs to treat infectious diseases, including COVID-19, based on the terms of the member’s insurance plan. READ MORE
2/17/2021 Medica

COVID-19 Testing Reimbursement Policy. READ MORE 

Reimbursement Rates for Coronavirus Diagnostic Testing:
 HCPCS U0001: $35.92
 HCPCS U0002: $51.33
 HCPCS U0003: $75.00 (effective date 4/14/2020)
 HCPCS U0004: $75.00 (effective date 4/14/2020)
 HCPCS U0005: $25.00 (Effective 1/1/2021)
 CPT 87635: $51.33
 HCPCS G2023: $23.46
 HCPCS G2024: $25.46
 HCPCS C9803: $24.67

3/16/2022 Medi-Cal

UPDATE - Frequency Limits Updated for COVID-19 Related Laboratory Codes. READ MORE 
Effective retroactively for dates of service on or after the effective dates of the codes listed within the chart, frequency limits are applied to select COVID-19 related laboratory codes. Procedure Codes are 86328, 86408, 86409, 86413, 86769, 87426, 87428, 87635, 87636, 87637, 87811, C9803, G2023, G2024, U0001, U0002, U0003, and U0004.

Medical justification with a Treatment Authorization Request/Service Authorization Request (TAR/SAR) to override the frequency limit for these laboratory codes may be allowed.

An Erroneous Payment Correction (EPC) will be implemented to reprocess denied claims with dates of service on or after the effective date of this billing policy, that were appropriately submitted based on the guidance published in this article, but erroneously denied because Medi-Cal had not yet implemented the system changes to support appropriation and adjudication. Providers may also elect to use this updated billing policy to correct and resubmit previously denied claims as described in the CIF Submission and Timeliness Instructions section of the Provider Manual.

>>>Click here to read past updates

4/13/2021 Medical Mutual of Ohio

UPDATE - You will be able to get the vaccine from in-network or out-of-network providers or locations during the national public health emergency declared by the U.S. Department of Health and Human Services. READ MORE

>>>Click here to read past updates

2/17/2021 Molina Effective 1/1/2021, only submitters of U0003 or U0004 that also include code U0005 will earn the higher payment of $100 per test. Submitters unable to support the additional code of U0005 high throughput tests will receive a lesser CMS payment of $75 per test. READ MORE 
11/2/2020 National Government Services - J6 A/B, JK A/B

UPDATE - 2021 Gap-Fill Request. National Government Services , the MAC for Jurisdictions JK and J6 is in receipt of the new laboratory test codes identified by CMS to be gap-fill priced for 2021. READ MORE 

>>>Click here to read past updates

6/29/2021 New York Medicaid

UPDATE - NY Dept. of Health 6/29/21. Letter to Clinical Laboratories (i.e. temporary approval) . READ MORE 

NY Dept of Health Letter to Clinical Labs (i.e. remote supervision). READ MORE 

>>>Click here to read past updates

5/25/2022 Noridian - JE & JF A & B

UPDATE - Billing and Coding: MolDX - Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726) - R3 - Effective June 02, 2022. READ MORE

Billing and Coding: MolDx - Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R3 - Effective June 02, 2022. READ MORE 

>>>Click here to read past updates

4/28/2021 Novitas Solutions - JH & JL

Revised Editing for Ordering/Referring Providers on Lab Claims. Because of the COVID-19 public health emergency (PHE), CMS previously amended regulations to remove the requirement that certain diagnostic tests are covered only when ordered by the treating  physician. READ MORE 

With CMS' revised policy, Medicare beneficiaries may receive coverage for one COVID-19 and related test without the order of a physician or non-physician practitioner. This revised policy includes the following codes:

U0001 - U0004 87635 86769
86328 87275 87276
87279 87400 87501-87503
87631 87804 87280
87240 87634 87807

 

3/2/2021 Novitas Solutions - JL

UPDATE - Clinical Diagnostic Laboratory Tests for COVID-19. Updates have been made to the reimbursement for U0003, U0004 and add-on code U0005. READ MORE 

  • U0003 = $75.00
  • U0004 = $75.00
  • U0005 = $25.00 - list separately in addition to either HCPCS code U0003 or U0004.

>>>Click here to read past updates

4/22/2022 Palmetto GBA - JM and JJ Enforcement Delay - MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing L38988. READ MORE 
4/28/2020 SummaCare

UPDATE -  Covid-19 Provider FAQ. READ MORE

>>>Click here to read past updates

1/25/2022 Texas Medicaid

UPDATE - QW Modifier Required for COVID-19 Testing Procedure Code 86328. Following changes to the Clinical Laboratory Improvement Amendments (CLIA) regulations, the Centers for Medicare and Medicaid Services (CMS) has released updated guidance for COVID-19 test billing effective September 23, 2020. READ MORE 

Effective for dates of service on or after September 23, 2020, COVID-19 testing procedure code 86328 will require the modifier QW when billed. Affected claims submitted with dates of service on or after September 23, 2020, may be reprocessed. When the claims are reprocessed, providers may receive additional payment, which will be reflected on Remittance and Status Reports.

Note: Providers are not required to appeal the claims unless they are denied for other reasons after the claims reprocessing is complete.

UPDATE - Effective January 12, 2021, for dates of service on or after January 1, 2021, the reimbursement rates for COVID-19 related procedure codes U0003, U0004, and U0005 have been updated. READ MORE       

>>>Click here to read past updates

3/31/2020 Tricare East Many military laboratories are operating under limited capacity due to the coronavirus pandemic. Tricare West providers may be asked by local military hospitals and clinics to direct patients to civilian network laboratories for tests military labs can’t perform in house. If Providers need to locate a new laboratory for Tricare patients, use the online directory on this page. READ MORE
3/31/2020 Tricare West Many military laboratories are operating under limited capacity due to the coronavirus pandemic. Tricare West providers may be asked by local military hospitals and clinics to direct patients to civilian network laboratories for tests military labs can’t perform in house. If Providers need to locate a new laboratory for Tricare patients, use the online directory on this page. READ MORE
6/1/2020 UnitedHealthcare

UPDATE - UHC summary of COVID-19 Dates by Program. READ MORE

>>>Click here to read past updates

3/27/2020 Washington Medicaid Effective April 1, 2020 for dates of service February 4, 2020, the following codes have been created to use for COVID-19 testing for FFS and MCO programs - U0001 and U0002. Effective for dates of service March 13, 2020, providers may also use CPT 87635 with the CR modifier. See ICD-10 codes posted by the payer for COVID-19 conditions provided by the CDC. For COVID-19 billing or coding policy questions, email HCAAH_COVID19@hca.wa.gov. READ MORE
5/23/2022 WPS Government Health Administrators - J5 A/B, J8 A/B June 2022 Local Coverage Determination (LCD) and Billing and Coding/Policy Article Updates. Last updated May 23 2022. READ MORE 
Jurisdictions J8 A&B, J5 A&B. Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing - LCD A58761 - Effective Date 5/17/22.